Cardinal Health closes Harvard Drug Group deal

DUBLIN, Ohio - Cardinal Health on Monday closed its $1.1 billion acquisition of The Harvard Drug Group, a distributor of generic pharmaceuticals and OTC medications.

 

In addition to enhancing the company's generic pharmaceutical distribution business, the acquisition expands Cardinal Health's existing telesales programs and capabilities; broadens the company's portfolio of over-the counter products; and brings specialized packaging offerings to meet the needs of hospital systems and other institutions.  

 

The Harvard Drug Group had revenues of approximately $450 million in 2014.